About Pierre Fabre Laboratories Oncology

Pierre Fabre Laboratories is one of Europe’s leading pharmaceutical laboratories and the world’s second-largest dermo-cosmetics company. Its Pharma activity covers 5 main therapeutic fields: oncology, dermatology, rare diseases, primary care and family health care. The Dermo-cosmetics & Personal Care portfolio includes international brands such as Eau Thermale Avène, Ducray, Klorane, A-Derma, René Furterer, Même Cosmetics, Darrow and Elgydium.  

For over 40 years, Pierre Fabre Laboratories has established itself as an international player in oncology, mastering the entire value chain from R&D to marketing. Its portfolio of oncology specialties covers colorectal, breast, lung and skin cancers, as well as certain hematologic malignancies and precancerous dermatological conditions such as actinic keratosis. In 2025, Pierre Fabre Laboratories’ revenues in oncology came to 565 million euros, 71% of which were generated by international sales, out of a total sales figure of 3.2 billion euros.

Based in southwest France since its creation, Pierre Fabre Laboratories manufactures nearly 90% of its products in France and employs 10,000 people worldwide. In 2025, its R&D budget amounted to 250 million euros, of which 67% is allocated to targeted therapies in oncology with 10 research and development programs underway.

Pierre Fabre Laboratories’ majority shareholder (86%) is an eponymous humanitarian Foundation. Employees constitute the company’s other shareholder. This capital structure guarantees the company’s independence, long-term vision and contribution to the common good. The dividends paid to the Pierre Fabre Foundation contribute to 35 healthcare-access programs deployed in 22 of the least developed countries in the world.

Pierre Fabre Laboratories’ CSR policy has been assessed by AFNOR Certification and has been awarded the “Exemplary” level of its CSR label (ISO 26 000 standard for sustainable development). 

For more information, visit www.pierre-fabre.com, @Laboratoires Pierre Fabre, @Pierre Fabre Oncology

Updated in April 2026